论文部分内容阅读
将12例应用门冬胰岛素30联合阿卡波糖治疗的脆性糖尿病患者(治疗组)与12例每天4次胰岛素(诺和灵R﹢诺和灵N)治疗的脆性糖尿病患者(对照组)对照,3月后进行空腹及餐后血糖、低血糖发生率及糖化血红蛋白的比较。结果:与对照组相比,治疗组血糖波动减小,低血糖的发生率降低(P<0.05),糖化血红蛋白得到改善。结论:门冬胰岛素30联合阿卡波糖治疗可有效改善脆性糖尿病的血糖控制。
Twelve patients with cryptococcosis (treatment group) treated with insulin aspart 30 plus acarbose and 12 patients with diabetes mellitus (control group) treated with four daily doses of insulin (Novolin® and noradrenaline N) were compared , After March fasting and postprandial blood glucose, hypoglycemia incidence and glycosylated hemoglobin comparison. Results: Compared with the control group, the treatment group decreased blood glucose, the incidence of hypoglycemia was decreased (P <0.05), and HbA1c was improved. Conclusion: Aspart 30 combined with acarbose can effectively improve blood glucose control in patients with fragile diabetes.